Celcuity is a clinical-stage, publicly traded biotechnology company seeking to extend the lives of cancer patients through the development of targeted therapies for the treatment of multiple solid tumor indications. The company was founded to develop a better way to treat the cellular drivers of tumor growth.
Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Gedatolisib phase 3 clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings. A Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going.
Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com
Company Details
- Employees
- 107
- Founded
- -
- Address
- 16305 36th Ave N, Minneapolis,mn 55446,united States
- Phone
- 763-473-0341
- Industry
- Biotechnology
- Website
- celcuity.com
- Keywords
- Representative jobs.
- HQ
- Minneapolis, MN
Celcuity Questions
Celcuity's helpline number is 763-473-0341
Celcuity's website is celcuity.com
Celcuity's LinkedIn profile is https://www.linkedin.com/company/celcuity
Celcuity has
107 employees.
View email and phone details for 107
employees at Celcuity.
Celcuity's industry is
Biotechnology
Celcuity's top competitors are
Vera Therapeutics, Inc.,
Corcept Therapeutics,
Kura Oncology, Inc.,
Immunocore,
Nuvalent, Inc.,
Revolution Medicines,
Vertex Pharmaceuticals,
Crinetics Pharmaceuticals,
Jazz Pharmaceuticals,
Summit Therapeutics, Inc..
Celcuity's categories are Biotechnology
Celcuity's founding year is 2012
